Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases
Allergan is jumping into the CRISPR business.
The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed at curing eye diseases. And the package includes Editas’ lead program for Leber Congenital Amaurosis (LCA10), which is currently wrapping preclinical research with an eye to moving into the clinic in possibly the first human CRISPR study in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.